Jeffrey Eisele - 16 Jan 2024 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Development Officer
Signature
/s/ David Watson, attorney-in-fact for Jeffrey Eisele
Issuer symbol
APLS
Transactions as of
16 Jan 2024
Transactions value $
$1,851,470
Form type
4
Filing time
17 Jan 2024, 12:24:09 UTC
Previous filing
28 Dec 2023
Next filing
18 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +19,508 +36.41% $0 73,088 16 Jan 2024 Direct F1
transaction APLS Common Stock Sale -$29,262 -438 -0.6% $66.81 72,650 16 Jan 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $1,880,732 +28,367 $66.3 28,367 16 Jan 2024 Common Stock 28,367 $66.3 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents an award of Restricted Stock Units granted 01/16/2024 that vests annually from grant date over a four year period subject to continued service.
F2 This represents shares sold to cover tax withholding on the Restricted Stock Units released on 01/12/2024.
F3 This represents a stock option award granted 01/16/2024 that vests over a four year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.